CY1122604T1 - Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης - Google Patents

Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης

Info

Publication number
CY1122604T1
CY1122604T1 CY20201100026T CY201100026T CY1122604T1 CY 1122604 T1 CY1122604 T1 CY 1122604T1 CY 20201100026 T CY20201100026 T CY 20201100026T CY 201100026 T CY201100026 T CY 201100026T CY 1122604 T1 CY1122604 T1 CY 1122604T1
Authority
CY
Cyprus
Prior art keywords
mcg
dose
equivalent
angiotasin
hypotension
Prior art date
Application number
CY20201100026T
Other languages
Greek (el)
English (en)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122604(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington University, A Congressionally Chartered Not-For-Profit Corporation filed Critical The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Publication of CY1122604T1 publication Critical patent/CY1122604T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20201100026T 2013-12-18 2020-01-13 Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης CY1122604T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
CY1122604T1 true CY1122604T1 (el) 2021-03-12

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100026T CY1122604T1 (el) 2013-12-18 2020-01-13 Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης

Country Status (25)

Country Link
US (7) US9220745B2 (en:Method)
EP (2) EP3607962B1 (en:Method)
JP (4) JP6824739B2 (en:Method)
KR (4) KR20220028125A (en:Method)
CN (4) CN111920939A (en:Method)
AU (3) AU2014364528C1 (en:Method)
BR (1) BR112016013961A2 (en:Method)
CA (1) CA2933601A1 (en:Method)
CY (1) CY1122604T1 (en:Method)
DK (2) DK3607962T3 (en:Method)
EA (1) EA037823B1 (en:Method)
ES (1) ES2771749T3 (en:Method)
FI (1) FI3607962T3 (en:Method)
HR (1) HRP20200009T1 (en:Method)
HU (1) HUE047062T2 (en:Method)
IL (1) IL246162B (en:Method)
LT (2) LT2986308T (en:Method)
MX (2) MX380968B (en:Method)
NZ (1) NZ721089A (en:Method)
PL (1) PL2986308T3 (en:Method)
PT (2) PT2986308T (en:Method)
RS (1) RS59804B1 (en:Method)
SI (1) SI2986308T1 (en:Method)
SM (2) SMT202000018T1 (en:Method)
WO (1) WO2015095535A1 (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
WO2015095535A1 (en) 2013-12-18 2015-06-25 The George Washington University, A Congressional Chartered Not-For-Profit Corporation Angiotensin ii alone or in combination for the treatment of hypotension
JP2017519799A (ja) * 2014-07-08 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 低血圧の治療方法
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
CA3010781A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201735913A (zh) * 2016-01-07 2017-10-16 拉荷亞製藥公司 投與血管加壓劑之方法
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) * 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US6592865B2 (en) 2001-06-04 2003-07-15 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
DE602006021600D1 (de) 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
CA2633013A1 (en) * 2005-12-30 2007-07-12 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
AU2007321111A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using Zn/pectin beads with a Eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
CA2742791A1 (en) 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
EP2593541A4 (en) 2010-07-14 2014-01-22 Cumberland Emerging Technologies Inc METHOD FOR THE TREATMENT OF HEPATORENAL SYNDROME AND HEPATIC ENZEPHALOPATHY WITH THROMBOXANE A2 RECEPTOR ANTAGONISTS
CN105592855A (zh) 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
WO2015095535A1 (en) 2013-12-18 2015-06-25 The George Washington University, A Congressional Chartered Not-For-Profit Corporation Angiotensin ii alone or in combination for the treatment of hypotension
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
JP2017519799A (ja) 2014-07-08 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 低血圧の治療方法
TW201735913A (zh) 2016-01-07 2017-10-16 拉荷亞製藥公司 投與血管加壓劑之方法
CA3010781A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法

Also Published As

Publication number Publication date
JP2025114753A (ja) 2025-08-05
JP2017501154A (ja) 2017-01-12
HRP20200009T1 (hr) 2020-03-20
JP7175506B2 (ja) 2022-11-21
PL2986308T3 (pl) 2020-05-18
KR20220028125A (ko) 2022-03-08
KR20230051721A (ko) 2023-04-18
US11096983B2 (en) 2021-08-24
SMT202000018T1 (it) 2020-03-13
RS59804B1 (sr) 2020-02-28
US20190070250A1 (en) 2019-03-07
MX2020011190A (es) 2020-11-13
LT3607962T (lt) 2026-01-12
IL246162A0 (en) 2016-07-31
CN111920939A (zh) 2020-11-13
WO2015095535A9 (en) 2016-07-14
SMT202500427T1 (it) 2026-01-12
US9220745B2 (en) 2015-12-29
US20160129072A1 (en) 2016-05-12
CA2933601A1 (en) 2015-06-25
AU2014364528A1 (en) 2016-06-30
CN119700926A (zh) 2025-03-28
ES2771749T3 (es) 2020-07-07
BR112016013961A2 (pt) 2017-10-10
US20190328827A1 (en) 2019-10-31
LT2986308T (lt) 2020-03-25
US20180193407A1 (en) 2018-07-12
SI2986308T1 (sl) 2020-03-31
KR20240154702A (ko) 2024-10-25
EP2986308A4 (en) 2017-01-11
KR20160117437A (ko) 2016-10-10
PT2986308T (pt) 2020-01-21
US20150164980A1 (en) 2015-06-18
NZ721089A (en) 2022-10-28
DK3607962T3 (da) 2025-11-17
US11559559B2 (en) 2023-01-24
HUE047062T2 (hu) 2020-04-28
MX2016008108A (es) 2017-03-09
US20230226141A1 (en) 2023-07-20
CN106061493A (zh) 2016-10-26
US10765722B2 (en) 2020-09-08
EP3607962B1 (en) 2025-08-13
AU2014364528C1 (en) 2021-01-07
JP6824739B2 (ja) 2021-02-03
MX380968B (es) 2025-03-12
KR102399383B1 (ko) 2022-05-19
US10028995B2 (en) 2018-07-24
JP2022137224A (ja) 2022-09-21
CN112546197A (zh) 2021-03-26
DK2986308T3 (en) 2020-01-27
AU2020277230A1 (en) 2020-12-24
EA037823B1 (ru) 2021-05-25
US10493124B2 (en) 2019-12-03
AU2024219851A1 (en) 2024-10-10
US20220047669A1 (en) 2022-02-17
EP2986308A1 (en) 2016-02-24
EP3607962A1 (en) 2020-02-12
AU2014364528B2 (en) 2020-08-27
WO2015095535A1 (en) 2015-06-25
PT3607962T (pt) 2025-11-18
EA201691258A1 (ru) 2016-11-30
FI3607962T3 (fi) 2025-11-24
IL246162B (en) 2020-03-31
JP2019214610A (ja) 2019-12-19
AU2014364528A9 (en) 2016-07-28
EP2986308B1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
CY1122604T1 (el) Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
MX387115B (es) Métodos para tratar la influenza.
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
CY1120490T1 (el) Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
AR120055A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX374354B (es) Método de curación de heridas.
MX373322B (es) Tratamiento de los síntomas asociados a terapia privación de andrógenos.
CY1122377T1 (el) Αργινινη για χρηση στη θεραπεια και/ή προληψη οστεοαρθριτιδας
MX2019014354A (es) Metodos para identificar nuevos regimenes de dosificacion.
MX2018004779A (es) Uso terapeutico de una solucion oftalmica acuosa esteril.
JOP20210347A1 (ar) طرق لعلاج فيروس نقص المناعة البشرية
CY1125036T1 (el) Μυκητοκτονος συνθεση αποτελεσματικη κατα του μηκυτα altenaria στα εσπεριδοειδη